Table 1. The frequency of T790M mutation in liquid biopsy in NSCLC patients with various demographic and clinical characteristics.
Older and younger patients as well as those with high and low sum of targeted lesions were divided based on the median of these parameters.
| Patients with T790M mutation—number (%) | Patients without T790M mutation—number (%) | Statistic—p (χ2) | ||
|---|---|---|---|---|
| Gender | Male | 6 (40) | 9 (60) | 0.7024 (0.146) |
| Female | 12 (46.1) | 14 (53.9) | ||
| Age | ≥67 years | 12 (54.5) | 10 (45.5 | 0.1395 (2.183) |
| <67 years | 6 (31.6) | 12 (68.4) | ||
| Tumor size | T0-T2 | 3 (21.4) | 11 (78.6) | 0.0368 (4.36) |
| T3-T4 | 15 (55.55) | 12 (44.45) | ||
| Lymph nodes metastases | N0-N1 | 11 (50) | 11 (50) | 0.397 (0.717) |
| N2-N3 | 7 (36.8) | 12 (63.2) | ||
| Distant metastases | M0 | 6 (46.1) | 7 (53.9) | 0.8875 (0.039) |
| M1 | 12 (42.9) | 16 (57.1) | ||
| RECIST | Stable disease | 5 (38.5) | 8 (61.5) | 0.6323 (0.229) |
| Progression | 13 (46.4) | 15 (53.6) | ||
| Sum of target lesions | ≥32 mm | 8 (36.4) | 14 (63.6) | 0.2951 (1.096) |
| <32 mm | 10 (52.6) | 9 (47.4) | ||
| Type of primary EGFR gene mutations | Exon 19 deletions | 10 (40) | 15 (60) | 0.4773 (1.479) |
| L858R substitution | 6 (60%) | 4 (40%) | ||
| Rare mutations | 2 (33.3) | 4 (66.7) | ||
| Type of primary EGFR gene mutations | Frequent mutations | 16 (45.7) | 19 (64.3) | 0.5772 (0.319) |
| Rare mutations | 2 (33.3) | 4 (66.7) | ||
| Type of EGFR TKIs | Erlotinib | 6 (37.5) | 10 (62.5) | 0.7985 (0.45) |
| Gefitinib | 3 (50%) | 3 (50) | ||
| Afatinib | 9 (47.4) | 10 (52.6) | ||
| Type of EGFR TKIs | First generation | 9 (40.9) | 13 (59.1) | 0.6775 (0.174) |
| Second generation | 9 (47.4) | 10 (53.6) |
Abbreviations: T–tumor, N–nodes, M–metastases, RECIST–Response Evaluation Criteria in Solid Tumors, TKIs–tyrosine kinase inhibitors, EGFR–epidermal growth factor receptor.